(Q40625806)

22 September 2017

title

In vitro and in vivo evaluations of THAM derived telomers bearing RGD and Ara-C for tumour neovasculature targeting (English)

1 reference

22 September 2017

1 reference

https://api.crossref.org/works/10.1016/S0223-5234(03)00150-8

21 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0223-5234(03)00150-8

21 March 2024

author

Christiane Contino-Pepin

2

object named as

C. Contino-Pépin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561481

21 March 2024

author name string

S. Jasseron

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561481

21 March 2024

J. C. Maurizis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561481

21 March 2024

M. Rapp

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561481

21 March 2024

B. Pucci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561481

21 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14561481

21 March 2024

publication date

1 September 2003

1 reference

full work available at URL

22 September 2017

https://api.elsevier.com/content/article/PII:S0223523403001508?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0223-5234(03)00150-8

https://api.elsevier.com/content/article/PII:S0223523403001508?httpAccept=text/plain

21 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0223-5234(03)00150-8

European Journal of Medicinal Chemistry

21 March 2024

published in

1 reference

22 September 2017

volume

38

1 reference

22 September 2017

issue

9

1 reference

22 September 2017

page(s)

825-836

1 reference

Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

1 reference

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

The rationale and future potential of angiogenesis inhibitors in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

An address system in the vasculature of normal tissues and tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Mechanisms of tumour metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Amphiphilic oligomers: a new kind of macromolecular carrier of antimitotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Control of tumour vascular permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

The alpha v beta 3 integrin "vitronectin receptor"

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

RGD and other recognition sequences for integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor).

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Angiogenesis: regulators and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Molecular addresses in blood vessels as targets for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Molecular mimicry of integrin ligation: therapeutic potential of arginine-glycine-aspartic acid (RGD) peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Disposition in rat of a new fluorinated, biocompatible, non-ionic telomeric carrier

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Synthesis and preliminary biological assessments of RGD bearing biocompatible telomers

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Cytostatic action of two nitrosoureas derived from cysteamine

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

A new quantitative method to evaluate the biodistribution of a radiolabelled tracer for melanoma using whole-body cryosectioning and a gaseous detector: comparison with conventional tissue combustion technology

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900150-8

7 January 2021

Cellular and Molecular Biology

32

42

335

Chehade

1996

1 reference

https://api.crossref.org/works/10.1016/S0223-5234(03)00150-8

THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY

21 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/S0223-5234(03)00150-8

21 March 2024

Identifiers

1 reference

22 September 2017

1 reference